Artax Biopharma Raises Series B Financing Extension


Artax Biopharma, Inc., a Cambridge, Mass.-based biotechnology company focused on transforming autoimmune disease treatment, completed an extension to its Series B financing led by Columbus Venture Partners.

The amount of the deal was not disclosed.

Led by Joseph Lobacki, Chief Executive Officer, Artax Biopharma is a biotechnology company focused on autoimmune disease immunomodulation science, developing an innovative small molecule approach to treat autoimmune disease that modulates the immune system to both treat autoimmune disease and allow the body to fight foreign pathogens. The company is examining a first-in-class oral immunomodulating agent as a new way to treat multiple autoimmune diseases without causing the immune suppression commonly associated with currently available autoimmune disease therapies.

Proceeds from the financing will be used to support activities for a planned Q4 2020 filing of a Clinical Trial Application (CTA) with the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) for AX-158. AX-158 is an oral small molecule, immunomodulating agent in development for the treatment of autoimmune diseases. It employs a novel mechanism of action that selectively modulates, or adjusts, T cell responses that play a critical role in immune system function.



Join the discussion